We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Detection of Pulmonary Embolism With CECT

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00351754
First Posted: July 13, 2006
Last Update Posted: January 7, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bracco Diagnostics, Inc
June 30, 2006
July 13, 2006
January 7, 2008
July 2006
Not Provided
Hounsfield Units (HU) measured at various levels of pulmonary arteries
Same as current
Complete list of historical versions of study NCT00351754 on ClinicalTrials.gov Archive Site
Presence of artifacts; global enhancement
Same as current
Not Provided
Not Provided
 
Detection of Pulmonary Embolism With CECT
Detection of Pulmonary Embolism Comparing Isovue-370 and Visipaque 320 Using 64-Slice Multi-Detector Computed Tomographic Angiography
To compare the vascular enhancement of the two contrast agents in pulmonary Multi-detector CTA
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Diagnostic
Pulmonary Embolism
Drug: Isovue
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
120
November 2006
Not Provided

Inclusion Criteria:

  • Patients 18 yrs or older
  • With suspected PE
  • Referred for MDCTA of pulmonary arteries
  • Signed informed consent

Exclusion Criteria:

  • Pregnant and lactating females
  • History of hypersensitivity to iodinated contrast agents
  • Hyperthyroidism or pheochromocytoma
  • Severe CHF
  • Renal impairment
  • Weight greater than 300 lbs
  • Pacemaker
  • Swan Ganz catheter
  • Defibrillator or other intrathoracic metallic vascular device
  • Received an investigational compound within 30 days of being in the study
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00351754
IOP 106
No
Not Provided
Not Provided
Not Provided
Bracco Diagnostics, Inc
Not Provided
Study Director: Steve Sireci, M.D. Bracco Diagnostics
Bracco Diagnostics, Inc
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP